Cormorant Asset Management as of March 31, 2018
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 49 positions in its portfolio as reported in the March 2018 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Nektar Therapeutics (NKTR) | 32.4 | $435M | 4.1M | 106.26 | |
| Anaptysbio Inc Common (ANAB) | 9.6 | $128M | 1.2M | 104.08 | |
| Apellis Pharmaceuticals (APLS) | 6.7 | $90M | 4.1M | 22.11 | |
| Mirati Therapeutics | 4.4 | $59M | 1.9M | 30.70 | |
| Inflarx Nv (IFRX) | 3.0 | $40M | 1.4M | 28.84 | |
| Blueprint Medicines (BPMC) | 3.0 | $40M | 432k | 91.70 | |
| Sage Therapeutics (SAGE) | 2.9 | $39M | 240k | 161.07 | |
| Myokardia | 2.8 | $37M | 767k | 48.80 | |
| Dicerna Pharmaceuticals | 2.6 | $34M | 3.6M | 9.56 | |
| Theravance Biopharma (TBPH) | 2.4 | $32M | 1.3M | 24.25 | |
| Rocket Pharmaceuticals (RCKT) | 2.1 | $29M | 1.5M | 18.75 | |
| G1 Therapeutics | 2.0 | $27M | 720k | 37.05 | |
| Omeros Corporation (OMER) | 1.9 | $26M | 2.3M | 11.17 | |
| Ascendis Pharma A S (ASND) | 1.8 | $24M | 372k | 65.40 | |
| Avexis | 1.8 | $24M | 192k | 123.58 | |
| Argenx Se (ARGX) | 1.7 | $22M | 279k | 80.44 | |
| Quotient | 1.5 | $20M | 4.3M | 4.71 | |
| Clearside Biomedical (CLSD) | 1.5 | $20M | 1.9M | 10.73 | |
| Tesaro | 1.5 | $20M | 350k | 57.14 | |
| Vanda Pharmaceuticals (VNDA) | 1.2 | $16M | 958k | 16.85 | |
| Neurocrine Biosciences (NBIX) | 1.2 | $16M | 191k | 82.93 | |
| Quanterix Ord (QTRX) | 1.1 | $14M | 848k | 17.04 | |
| Menlo Therapeutics | 0.9 | $13M | 337k | 37.58 | |
| Array BioPharma | 0.8 | $11M | 669k | 16.32 | |
| Audentes Therapeutics | 0.7 | $9.7M | 323k | 30.05 | |
| Aclaris Therapeutics (ACRS) | 0.7 | $9.2M | 526k | 17.52 | |
| Reata Pharmaceuticals Inc Cl A | 0.7 | $9.2M | 450k | 20.51 | |
| Abeona Therapeutics | 0.6 | $7.9M | 549k | 14.35 | |
| Collegium Pharmaceutical Inc Common Stock Usd (COLL) | 0.6 | $7.3M | 287k | 25.55 | |
| Biohaven Pharmaceutical Holding | 0.6 | $7.3M | 285k | 25.76 | |
| Sangamo Biosciences (SGMO) | 0.5 | $7.3M | 382k | 19.00 | |
| Zai Lab (ZLAB) | 0.5 | $7.1M | 333k | 21.35 | |
| Kadmon Hldgs | 0.5 | $7.0M | 1.6M | 4.25 | |
| Gemphire Therapeutics | 0.5 | $6.8M | 1.0M | 6.51 | |
| Contrafect | 0.4 | $5.4M | 3.4M | 1.59 | |
| Heron Therapeutics (HRTX) | 0.4 | $5.3M | 191k | 27.60 | |
| Solid Biosciences | 0.4 | $5.1M | 686k | 7.49 | |
| Arena Pharmaceuticals | 0.4 | $4.9M | 125k | 39.50 | |
| Intec Pharma | 0.4 | $4.9M | 774k | 6.32 | |
| Trillium Therapeutics, Inc. Cmn | 0.3 | $4.1M | 573k | 7.20 | |
| Minerva Neurosciences | 0.3 | $3.8M | 608k | 6.25 | |
| Protagonist Therapeutics (PTGX) | 0.2 | $3.3M | 382k | 8.59 | |
| Evolus (EOLS) | 0.2 | $3.1M | 342k | 9.03 | |
| Acceleron Pharma | 0.2 | $2.8M | 72k | 39.10 | |
| Marinus Pharmaceuticals | 0.1 | $1.8M | 478k | 3.82 | |
| Jounce Therapeutics | 0.1 | $1.9M | 83k | 22.35 | |
| Cellectar Biosciences Equity Warrants *w | 0.0 | $5.8k | 53k | 0.11 | |
| Oncobiologics Inc *w exp 02/18/201 | 0.0 | $17k | 417k | 0.04 | |
| Oncobiologics Inc *w exp 05/18/201 | 0.0 | $17k | 417k | 0.04 |
